J&J: EU green light for Carvykti in multiple myeloma
April 22, 2024 at 10:34 am EDT
Share
Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission (EC) has approved a type II variant for Carvykti (ciltacabtagene autoleucel; cilta-cel).
This latest approval is for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI), and who have demonstrated clinical disease progression and are refractory to lenalidomide.
With this approval, cilta-cel becomes the first CAR-T cell therapy approved in Europe for the treatment, from the first relapse onwards, of patients with MMRR,
' Today's approval marks an important step forward for eligible patients with multiple myeloma, who can now benefit from treatment with cilta-cel earlier in their treatment journey, where it has the potential to transform outcomes and alter the trajectory of their disease', emphasizes Edmond Chan, Head of Hematology Therapeutic Area at Johnson & Johnson Innovative Medicine.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
JOHNSON & JOHNSON 
